Rapid access to high-quality proteins is essential for accelerating early discovery, screening, and proof-of-concept studies. However, traditional expression systems can be time-consuming and unpredictable. In this webinar, experts from Integrated DNA Technologies (IDT), Nuclera, and Aldevron will present a streamlined, end-to-end solution that dramatically shortens the DNA-to-protein timeline. Presenters from three collaborating companies will share the following:
Senior Commercial Product Manager, SynBio,
Integrated DNA Technologies
Lucy Xu is a product leader with over a decade of experience in biotechnology and a focus on strategic growth across the global life sciences market. At IDT, she leads product strategy for Synthetic Biology, supporting a wide range of applications including antibody discovery, protein engineering and therapeutic development. Lucy has driven multimillion dollar product growth and led global market expansion initiatives. She holds a B.S. in Bioengineering from UC San Diego.
Inside Sales Specialist,
Nuclera
Lawrence Welch is an inside sales specialist at Nuclera, where he supports the adoption of the company’s automated, cell-free protein expression system, eProtein Discovery™. He earned his undergraduate degree in Pharmacology with industrial placement experience at the University of Manchester and completed his PhD in Sean Munro’s lab at the MRC Laboratory of Molecular Biology. Since transitioning to a commercial role in 2025, Lawrence has focused on helping researchers use cutting-edge microfluidic technology to accelerate protein discovery.
Sr. Scientist I-Protein R&D,
Aldevron
Joel Francis is a senior scientist in the protein R&D group at Aldevron. Joel completed his Bachelor's degree at Grand Valley State University where he majored in Cell & Molecular Biology and minored in Chemistry. He continued his training as a graduate student at Stanford University Department of Biology. His research revolved around the enzymology and functions of protein lysine methylation in gene expression regulation and cancer biology. Since joining Aldevron in 2023, his primary work revolves around the CRISPR Gene Editing product line.